CLAIMS

1. An affinity column for isolating nucleic acid from a sample, the column comprising: a first solid support in fluid communication with a second solid support, said first solid support comprising at least one reagent and said second solid support comprising at least one nucleic acid binding moiety wherein the nucleic acid binding moiety is an antibiotic; and a third solid support, wherein said third solid support is in removable fluid communication with said second solid support.

2. The affinity column of claim 1, wherein the at least one reagent is capable of disrupting the sample.

3. The affinity column of claim 1, wherein the at least one reagent is a cell disruption reagent or a virus disruption reagent.

4. The affinity column of any one of claims 1-3, wherein the first solid support comprises a cell binding moiety, a reagent for disrupting the sample, or an enzyme.

5. The affinity column of claim 4, wherein the first solid support comprises: (i) a cell binding moiety, a reagent for disrupting the sample, or an enzyme; or(ii)a cell binding moiety and a reagent for disrupting the sample.

6. The affinity column of any of claims 1-5, wherein the antibiotic is selected from the group consisting of amikacin, gentamycin, kanamycin, neomycin, streptomycin, tobramycin, WP631, WP762, Daunorubicin, Echinomycin, and paraomycin.

7. The affinity column of any one of claims 1-3, wherein the third solid support comprises one or more nucleic acid stabilizing molecules, elution buffer, and/or molecules that form an elution buffer when mixed with an aqueous solution.

8. An affinity matrix for the isolation of nucleic acid from a sample, said affinity matrix comprising at least one nucleic acid binding moiety bound to a solid support, wherein the at least one nucleic acid binding moiety is chosen from the group consisting of an antibiotic.

9. A method for isolating nucleic acid from a sample comprising at least one nucleic acid, the method comprising:
contacting an affinity matrix with the sample, wherein said affinity matrix comprises at least one nucleic acid binding moiety bound to a solid support such that said nucleic acid is bound by the nucleic acid binding moiety, and further wherein the at least one nucleic acid binding moiety is an antibiotic, and eluting the nucleic acid from the affinity matrix.

10. The affinity column of claim 7, wherein said elution buffer comprises a chaotrope.

11. The affinity matrix of claim 8, wherein the antibiotic is selected from the group consisting of amikacin, gentamycin, kanamycin, neomycin, streptomycin, tobramycin, WP631, WP762, Daunorubicin, Echinomycin, and paraomycin.